B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist.

OBJECTIVE To elucidate the usefulness of plasma B-type natriuretic peptide (BNP) values for evaluating adverse effects of pergolide or cabergoline on cardiovalvulopathy in patients with Parkinson disease. METHODS Twenty-five patients treated with pergolide or cabergoline (ergot group) and 25 patients never treated with ergot derivatives (non-ergot group… CONTINUE READING